User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life

  1. Hirsch Irl B., Insulin Analogues, 10.1056/nejmra040832
  2. Lavens A, Initiative pour la Promotion de la qualite et de l’Epidemiologie du Diabete sucre (IPQED) – Rapport resultats 2014 – Direction operationnelle Sante Publique et Surveillance (2016)
  3. Shiramoto M., Eto T., Irie S., Fukuzaki A., Teichert L., Tillner J., Takahashi Y., Koyama M., Dahmen R., Heise T., Becker R. H. A., Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes, 10.1111/dom.12415
  4. Becker RH, Diabetes Care, 38, 637 (2015)
  5. Home Philip D., Bergenstal Richard M., Bolli Geremia B., Ziemen Monika, Rojeski Maria, Espinasse Melanie, Riddle Matthew C., New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4), 10.2337/dc15-0249
  6. Ashwell S. G., Gebbie J., Home P. D., Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart, 10.1111/j.1464-5491.2006.01913.x
  7. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., Cordoni C., Costa E., Brunetti P., Bolli G. B., Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro, 10.2337/diabetes.49.12.2142
  8. Koehler G., Treiber G., Wutte A., Korsatko S., Mader J. K., Semlitsch B., Pieber T. R., Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes, 10.1111/dom.12178
  9. Gradišer Marina, Berković Maja Cigrovski, Bilić-Ćurčić Ines, Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study, 10.1016/j.diabres.2017.03.036
  10. Goldman Jennifer, Kapitza Christoph, Pettus Jeremy, Heise Tim, Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice, 10.1080/03007995.2017.1335192
  11. Bolli G. B., Riddle M. C., Bergenstal R. M., Ziemen M., Sestakauskas K., Goyeau H., Home P. D., , New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3), 10.1111/dom.12438
  12. Ritzel R., Roussel R., Bolli G. B., Vinet L., Brulle-Wohlhueter C., Glezer S., Yki-Järvinen H., Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes, 10.1111/dom.12485
Bibliographic reference Oriot, Philippe ; Jérémie, Wawrzyniak ; Buysschaert, Martin. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life. In: Expert Review of Endocrinology & Metabolism, Vol. 13, no. 3, p. 167-171 (2018)
Permanent URL http://hdl.handle.net/2078.1/215753